NASDAQ:NAMSW NewAmsterdam Pharma (NAMSW) Stock Price, News & Analysis $11.00 0.00 (0.00%) As of 09:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsOwnershipSEC Filings About NewAmsterdam Pharma Stock (NASDAQ:NAMSW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get NewAmsterdam Pharma alerts:Sign Up Key Stats Today's Range$10.41▼$11.0050-Day Range$10.93▼$18.3852-Week Range$10.41▼$30.45Volume1,547 shsAverage Volume2,103 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on developing therapies for dyslipidemia and other conditions associated with cardiovascular disease. The company’s lead investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid measures in patients who remain inadequately controlled on existing treatments. Obicetrapib is being evaluated in late-stage clinical development, including as a potential treatment for patients with established cardiovascular disease and those who are unable to achieve sufficient lipid control with currently available therapies. NewAmsterdam has also studied obicetrapib in combination with ezetimibe and other lipid-lowering approaches. The company does not have a marketed product and remains focused on clinical development, regulatory activities and potential commercialization. NewAmsterdam Pharma has roots in the Netherlands and operates internationally through clinical research and development activities. The company’s leadership has included Michael Davidson as chief executive officer, supported by executives and scientific advisers with experience in cardiovascular medicine, lipid disorders and pharmaceutical development.AI Generated. May Contain Errors. Read More Receive NAMSW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NAMSW Stock News HeadlinesNewAmsterdam Pharma Begins Phase 2b Preclinical Alzheimer’s TrialSeptember 29, 2026 | tipranks.comEU Approval of Obicetrapib Products Strengthens NewAmsterdamSeptember 21, 2026 | tipranks.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 7 at 1:00 AM | Stansberry Research (Ad)Analyst Reiterates Buy on NewAmsterdam Pharma as PREVAIL Study Changes and Interim Analysis Boost Confidence in Obicetrapib’s Cardiovascular OutcomesSeptember 18, 2026 | tipranks.comNewAmsterdam Pharma: Potential Coupled With UncertaintySeptember 8, 2026 | seekingalpha.comNewAmsterdam Pharma Appoints New Principal Accounting OfficerAugust 14, 2026 | tipranks.comNewAmsterdam Pharma reports $3.7 million second quarter revenueAugust 5, 2026 | quiverquant.comQNewAmsterdam Pharma: Obicetrapib Is More Than Another LDL-Lowering PillJuly 25, 2026 | seekingalpha.comSee More Headlines NAMSW Stock Analysis - Frequently Asked Questions How have NAMSW shares performed this year? NewAmsterdam Pharma's stock was trading at $22.99 at the start of the year. Since then, NAMSW stock has decreased by 52.2% and is now trading at $11.00. How do I buy shares of NewAmsterdam Pharma? Shares of NAMSW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/07/2026Next Earnings (Estimated)11/11/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 NAMSW's financial health is in the Yellow zone, according to TradeSmith. NAMSW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NAMSW CIK1936258 Webwww.newamsterdampharma.com Phone31 35 206 2971FaxN/AEmployees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$7.12 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:NAMSW) was last updated on 10/7/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMSW Stock Alerts